Introduction
The COVID-19 pandemic called for unprecedented policies by governments around the world to counter its spread. Most European countries have implemented social distancing and shelter-in-place measures. These measures are comparable to generalised quarantine and prevent the spread of the virus by restricting the movement and social interactions of people who are potentially exposed.1 As of 3 May 2020, 2.5 billion people are in lockdown.2 In France, these measures have been enforced since 17 March 2020. Several studies have reported the negative effects of quarantine on stress or depression.3–5
Peritraumatic distress (PD) is defined as the emotional and physiological distress experienced during and/or immediately after a traumatic event. It is associated with a higher risk and severity of post-traumatic stress disorder (PTSD).6 7 The Peritraumatic Distress Inventory (PDI) was created to assess the emotional and physiological experience of individuals during a traumatic event.8 Studies have shown that PDI has a good internal consistency, stability and validity. PDI items can be grouped into factors that better reflect and predict PD and PTSD: negative emotions (items 1, 2, 3, 5, 6, 8 and 10) and perceived life threat and bodily arousal (items 4, 7, 9, 11, 12 and 13).9 It has also been shown that a PDI score ≥14 predicts full or partial PTSD 6 weeks postinjury.10
The main objective of this study was to assess PD in France during the COVID-19 crisis in at-risk patients. The secondary objectives were to describe the patients’ characteristics that can be used to predict the risk of PD and PTSD. In order to do so, we built an e-cohort: users of four medical chatbots designed to support patients with (1) asthma, (2) breast cancer, (3) depression and (4) migraine were invited to participate in an online survey. A chatbot is a software leveraging artificial intelligence to provide a natural language conversation with a user. They can be used to monitor patients during treatment or to collect patient-reported outcomes.11 Vik chatbots, developed by Wefight, have been shown to provide assistance with patient support and adherence to treatment.12 They are also capable of providing medical information to breast cancer patients with a level of quality comparable with that of physicians, as shown in the phase III randomised controlled trial INCASE (NCT03556813).13 The ‘Vik Asthme’ chatbot is dedicated to information and management of asthma-related symptoms, the ‘Vik Breast’ chatbot has been specialised for the management of patients with breast cancer, the ‘Vik Depression’ chatbot provides assistance to patients with symptoms of depression and the ‘Vik Migraine’ chatbot is helpful for patients with chronic migraine.
People with asthma are populations at increased risk of severe viral respiratory infections that can also induce exacerbations. The SARS-CoV-2 can induce asthma exacerbations that are a source of additional stress for asthma patients. Initial data show that patients with asthma do not appear to be over-represented in patients with COVID-19.14 15 In order to mitigate the lack of pathology control and treatment adherence during travel restrictions, the French government has implemented solutions to facilitate the renewal of treatment in the long term.16 In addition, 60 000 hospitalisations are attributable to asthma every year in France.17 This pandemic is of significant concern in patients with cancer who are at high risk of complications due to several predisposing factors.18–20 In patients with breast cancer, management must be tailored and cannot be delayed. European countries have increased the use of telehealth systems to reduce the number of hospital visits. In Italy, these changes in care led to the patients having many questions, which can generate severe stress or anxiety.21 The initial studies conducted in China following the COVID-19 pandemic have shown the impact on the mental health of healthcare workers, with an increased risk of depression and anxiety.22 Patients already diagnosed with depressive disorder could be at a high risk of distress during the COVID-19 pandemic. Finally, migraine is a pathology with a high prevalence: it is estimated to be between 17% and 21% in adults aged 18–65 years23 with a sex ratio of three women to one man.24 Despite its high prevalence, migraine remains an underdiagnosed and undertreated condition in the general population. Migraine can have a significant impact on the patient’s quality of life.25 Migraines can worsen in times of stress. This period of pandemic can generate a new source of stress and aggravate the pathology.